Moderate therapeutic hypothermia (33 °C during the first 24 h) in patients with coma who have been resuscitated from cardiac arrest with a nonshockable rhythm significantly improves survival with favourable neurological outcomes at day 90 compared with targeted normothermia. This finding comes from the HYPERION trial, an open-label, randomized, controlled trial that included 581 patients admitted to the intensive care unit with nonshockable cardiac arrest owing to cardiac or noncardiac causes. At day 90, patients who received moderate-hypothermia management had higher survival with a favourable neurological outcome (defined as Cerebral Performance Category score 1 or 2) than those who received targeted normothermia (10.2% versus 5.7%, P = 0.04). No differences were observed between the two groups for mortality at 90 days or the incidence of adverse events.